The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.

Hereditary cancer predisposition gene testing allows the identification of individuals at high risk of cancer that may benefit from increased surveillance, chemoprevention, and prophylactic surgery. In order to implement clinical genetic strategies adapted to each population's needs and intrinsic genetic characteristic, this review aims to present the current status of knowledge about the spectrum of BRCA pathogenic variants in Latin American populations. We have conducted a comprehensive review of 33 studies published between 1994 and 2015 reporting the prevalence and/or spectrum of BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) variants. The combined sample size for these studies consisted of 4835 individuals from 13 countries in Latin America and the Caribbean, as well as in Hispanics in the United States. A total of 167 unique pathogenic variants have been reported in the existing literature. In unselected breast cancer cases, the prevalence ranged from 1.2 to 27.1%. Some countries presented a few recurrent pathogenic variants, while others were characterized by diverse, non-recurrent variants. The proportion of BRCA pathogenic variants shared between Hispanics in the United States and Latin American populations was estimated at 10.4%. Within Latin America and the Caribbean, 8.2% of the BRCA variants reported were present in more than one country. Countries with high prevalence of BRCA pathogenic variants may benefit from more aggressive testing strategies, while testing of recurrent variant panels might present a cost-effective solution for improving genetic testing in some, but not all, countries.

Introduction

Worldwide, breast cancer is the most common female cancer and the most common cause of female cancer-related death [1]. Breast cancer is a heterogeneous disease defined by various molecular subtypes, each one with an associated risk profile and treatment recommendations [2, 3]. Several loci of high, moderate, and low penetrance have been implicated in inherited risk of breast cancer [4, 5]. The genetic predisposition to breast cancer can be described as a continuum from a strong genetic contribution to a weaker polygenic genetic contribution with an environmental component.

Over 20 years ago, the BRCA1 and BRCA2 genes were identified as highly penetrant susceptibility genes for hereditary breast and ovarian cancers [6, 7]. Inactivating variants in those tumor suppressors account for approximately 16 % of the familial risk of breast cancer [8] and represent 5–10 % of all breast cancers [9]. Women carrying a BRCA mutation are estimated to have a cumulative cancer risk by age of 70 years of up to 87 and 54 % for breast and ovarian cancer, respectively [10-16]. They also have modest to marked increases in the lifetime risk of developing other cancer types such as colorectal, gastric, gallbladder and bile duct, malignant melanoma, pancreatic, prostate, and uterine cancers [10, 14, 16, 17]. The early identification of individuals at risk by genetic testing has been shown to be associated with increased surveillance and risk-reduction strategies ultimately leading to diagnosis of early stage tumors and improved outcomes [18, 19]. However, effective identification of BRCA1/2 mutation carriers depends on the availability and access to genetic counseling and testing of at-risk individuals.

A significant portion of populations inhabiting Central and South America as well as certain islands of the Caribbean share an official language derived from Latin, majorly Spanish or Portuguese. Despite this common heritage from the colonization era, each region of Latin America and the Caribbean (hereby referred to as Latin America) is often characterized by unique geography, culture, politics, and socioeconomic factors [20]. In the USA, Hispanics (defined by the U.S. Census Bureau a person of Cuban, Mexican, Puerto Rican, South or Central American—except for Brazil, or other Spanish culture or origin regardless of race) make up 16.3 % of the population and accounted for 56 % of the national population growth between 2000 and 2010, which makes this group the fastest growing minority in the country [21].

Despite lower incidence of breast cancer in Latin America populations when compared to Europe or the USA, the mortality-to-incidence ratio is significantly higher in the former region [21, 22]. This is in part due to poor access to cancer care and presentation at later stages [22]. For instance, it is estimated that 58 % of the breast cancers in Mexico are detected at stage III–IV [23]. In this population, the high cost associated with cancer care was attributed to late diagnosis, suggesting a need for the implementation of better prevention and detection strategies [24]. However, in several regions of Latin America, genetic testing is either not available or the associated cost is still prohibitive for a large proportion of individuals at risk [22].

There is limited information available regarding population-specific risks and very few systematic studies of the prevalence of genetic variants predisposing to breast cancer relevant to the populations of Latin America. Here we review the current knowledge about BRCA1 and BRCA2 variants in women from Latin America, the Caribbean, and Hispanics in the United States with the objective of identifying areas in need of further research and avenues for improving access to genetic testing for hereditary cancers.

The BRCA1 and BRCA2 mutation spectrum in Latin America

In recent years, increasing accessibility of next-generation sequencing (NGS) has resulted in its increased use in clinical genetic testing [25]. NGS approaches allows the cost-effective interrogation of multiple targets and has driven the expansion from BRCA1 and BRCA2 testing to the so-called ‘panel testing,’ in which a number of additional high- and moderate-penetrance hereditary cancer genes (demonstrated and suspected) are included [26]. Despite these advances, the cost of comprehensive BRCA1 and BRCA2 analysis is still prohibitive for low income individuals in these countries. Importantly, although the technical sensitivity of these assays is very high and virtually all variants can be accurately detected, our ability to clinically annotate these variants has lagged.

As a solution, amplicon-based single-site panels of recurrent Latin American BRCA pathogenic variants that would constitute the first line of screening of at-risk individuals prior to performing comprehensive BRCA analysis have been developed. Such model of tiered testing has been widely successful in the Ashkenazi Jewish population in which three common pathogenic variants explain 78.4 % of the cases [27]. The development of a clinically useful panel in Latin America will require knowledge of the pathogenic variant spectrum in each region or country and depend on the presence of recurrent variants explaining a majority of the hereditary breast and ovarian cancer cases.

To provide a comprehensive picture we have conducted a literature review of the BRCA1 and BRCA2 variants identified in Latin America (Supplementary Fig. 1). Between 1994 and August 2015, 33 publications reported BRCA variants in populations from 13 countries of Central and South America, the Caribbean, and Hispanic/Latino populations from the US. Taken together, these studies have screened a total of 4835 individuals and identified 167 different pathogenic variants (Supplementary Table 1). Table 1 summarizes the characteristics of the cohorts, the prevalence of the BRCA variants reported, and screening methods for each of the study reviewed.

Table 1

Characteristics of the cohorts and BRCA1 and BRCA2 mutation prevalence from 27 publications in 13 countries of Latin America and the Caribbean

Country	Cohort size	Cohort type	Prevalence	BRCA screening methods	Large rearrangements screening	Reference
Argentina	94	BC and/or OC cases, with early onset no FH (n = 37); BC and/or OC cases with onset at any age and FH (BC, OC) (n = 57)	16.2–35.8	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	n/a	Solano et al. [67]
Argentina	40	BC and/or OC cases of Ashkenazi Jewish origin with FH (BC, OC)	35.7–58.3	Screening for three founder Ashkenazi Jewish mutations	n/a	Solano et al. [67]
Bahamas	204	Unselected invasive BC cases	27.1	Screening for six BRCA1 African-American founder mutations, direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	MLPA panel	Donenberg et al. [42], Akbari et al. [41]
Brazil	31	BC cases selected for early onset, bilaterality and/or FH (BC, OC, male BC)	12.9	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by SSCP, confirmation of the variants by direct sequencing	n/a	Dufloth et al. [44]
Brazil	402	Unselected invasive BC cases	2.3	Screening for three founder Ashkenazi Jewish mutations using FMPA, BRCA1 and BRCA2 coding exons and intron/exon junctions screening by PTT, DGGE, DHPLC, confirmation of the variants by direct sequencing	BRCA1 exon 13 6 kb duplication	Gomes et al. [33]
Brazil	612	Index cases from families with history of BC and/or OC	3.4	BRCA1 exon 11 and BRCA2 exon 10 and 11 screening by PTT, confirmation of the variants by direct sequencing	n/a	Esteves et al. [45]
Brazil	137	Personal and/or FH suggestive of HBOC	5.1	Screening for three founder Ashkenazi Jewish mutations by direct sequencing	n/a	Ewald et al. [46]
Brazil	106	Personal and/or FH suggestive of HBOC	8.5	BRCA1 coding exons and intron/exon junctions screening by SSCP, confirmation of the variants by direct sequencing; BRCA2 two mutations panel	n/a	Felix et al. [47]
Brazil	120	Personal and/or FH suggestive of HBOC	22.5	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	MLPA panel	Silva et al. [48]
Chile	54	BC and/or OC cases with FH (BC, OC, other cancers)	20.4	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by HDA, PTT, SSCP, and confirmation of the variants by direct sequencing	n/a	Gallardo et al. [69]
Chile	326	Index cases from families with history of BC and/or OC	7.1	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by CSGE, confirmation of the variants by direct sequencing, large rearrangement screening by MLPA	MLPA panel in a subset of cases	Gonzalez-Hormazabal et al. [70]
Colombia	53	BC cases with FH of BC and/or OC	24.5	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by SSCP, DHPLC and PTT, confirmation of the variants by direct sequencing	n/a	Torres et al. [65]
Colombia	766	Unselected BC cases	4.5	Screening for a panel of five mutations previously observed in Colombia using restriction digestion analysis	n/a	Torres et al. [34]
Colombia	96	Unselected OC cases	15.6	Screening for a panel of 50 BRCA1 and 46 BRCA2 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencing	n/a	Rodríguez et al. [66]
Colombia	280	Unselected BC cases	1.2	BRCA1 exon 11 and BRCA2 exon 10 and 11 screening by PTT, screening for a panel of 96 recurrent Hispanic mutations by Sequenom and confirmation of the variants by direct sequencing.	n/a	Hernandez et al. [35]
Costa Rica	111	BC cases with FH of BC	4.5	Screening for three founder Ashkenazi Jewish mutations using FMPA, BRCA1 exon 11 and BRCA2 exon 10 and 11 screening by PTT, confirmation of the variants by direct sequencing	n/a	Gutierrez-Espeleta et al. [58]
Cuba	307	Unselected BC cases	2.6	Screening for three founder Ashkenazi Jewish mutations using FMPA, BRCA1 and BRCA2 coding exons and intron/exon junctions screening by PTT, DGGE, and direct sequencing	BRCA1 exon 13-6 kb duplication	Rodriguez et al. [36]
Mexico	51	BC cases with early onset and/or FH (BC, OC)	6.3	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by HDA, confirmation of the variants by direct sequencing.	n/a	Ruiz-Flores et al. [49]
Mexico	22	Early onset BC cases	9.1	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by HDA, confirmation of the variants by direct sequencing.	n/a	Calderón-Garcidueñas et al. [50]
Mexico	39	BC and OC cases selected for early onset (BC) and/or FH (BC, OC, other BRCA associated cancers)	10.2	Direct sequencing (next-generation) of BRCA1 and BRCA2 coding exons and intron/exon junctions	n/a	Vaca-Paniagua et al. [51]
Mexico	188	BC and OC cases; unselected for FH	21.3	Screening for a panel of 115 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencing; Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions for patients with negative panel result	MLPA panel	Villarreal-Garza et al. [37]
Mexico	815	BC cases; unselected for FH	4.3	BRCA1 exon 11 and BRCA2 exon 10 and 11 screening by PTT, confirmation of the variants by direct sequencing; screening for a panel of 26 mutations found in Mexican	BRCA1 exon 9–12 deletion	Torres-Mejia et al. [38]
Mexico	190	Triple-negative BC cases unselected for FH	23.0	Screening for a panel of 115 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencing	BRCA1 exon 9–12 deletion	Villarreal-Garza et al. [52]
Peru	266	BC cases; unselected	4.9	Screening for a panel of 115 Hispanic mutations using Sequenom MassArray and confirmation of the variants by direct sequencing	n/a	Abugattas et al. [39]
Puerto Rico	23	BC and unaffected individuals with FH (BC, OC)	47.8	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	Myriad Genetics1	Dutil et al. [32]
Uruguay	42	BC cases with FH (BC, OC)	17	BRCA1 and BRCA2 coding exons and intron/exon junctions screening by PTT and HDA, confirmation of the variants by direct sequencing	n/a	Delgado et al. [59]
US Hispanics	19	Personal and/or FH suggestive of HBOC	42	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	Myriad Genetics1	Mullineaux et al. [53]
US Hispanics	140	Sibships, sisters affected with BC and/or OC and unaffected sisters	0.7	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	n/a	McKean-Cowdin et al. [54]
US Hispanics	110	BC and/or OC cases; unaffected individuals with FH of BC and/or OC	30.9	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	Myriad Genetics1 or BRCA1 exon 9–12 del	Weitzel et al. [57]
US Hispanics	393	BC and/or OC cases	3.5	BRCA1 only, DGGE or direct sequencing of BRCA1 coding exons and intron/exon junctions	n/a	John et al. [56]
US Hispanics	78	BC and/or OC cases; unaffected individuals with FH of BC and/or OC	17.9	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	Myriad Genetics1	Vogel et al. [55]
US Hispanics	746	BC and/or OC cases; unaffected individuals with FH of BC and/or OC	25.3	Direct sequencing of BRCA1 and BRCA2 coding exons and intron/exon junctions	Myriad Genetics1	Weitzel et al. [31]
Venezuela	58	BC cases selected for early onset, bilaterality and/or FH (BC, OC, male BC).	17.2	Founder Jewish mutations by FMPA, BRCA1 and BRCA2 coding exons and intron/exon junctions screening by DGGE, confirmation of the variants by direct sequencing.	n/a	Lara et al. [68]

Founder Ashkenazi Jewish mutations are BRCA1 185delAG, BRCA1 5382insC, BRCA2 6174delT

BC breast cancer, OC ovarian cancer, FH family history, SSCP single strand conformation polymorphism, DGGE denaturing gradient gel electrophoresis, PTT protein truncation test, HDA heteroduplex analysis, FMPA fluorescent multiplexed-PCR analysis, CSGE conformation sensitive gel electrophoresis, MLPA multiplex ligation-dependent probe amplification

1After 2002, Myriad Genetics Clinical testing includes at least a BRCA1 5′ rearrangement panel (exon 13 del 835 kb, exon 13 ins 6 kb, exon 22 del 510, exon 8 to 9 del 71 kb, exon 14-20 del 26 kb)

The size of the cohorts ranged from 19 to 815 individuals, the majority identified through hospital or clinic-based recruitment strategies (Table 1). Several methodological factors preclude a systematic comparison across studies. There was significant variation in the inclusion criteria from unselected cases to cases selected for family history and/or personal history criteria such as age of onset and tumor molecular profile. Indirect mutation detection methods or approaches that restrict the search to panels of known mutations are expected to detect only a fraction of the variants present in the sample screened. For instance, the sensitivity of single-stranded conformation polymorphism (SSCP) ranges from 50 to 96 %, while conformation-sensitive gel electrophoresis (CSGE) and for the protein truncation test (PTT) are estimated to detect only 75 and 76 % of the BRCA1 and BRCA2 variants, respectively [28].

Early BRCA testing focused on the detection of single nucleotide variants (point mutations) and small insertions or deletions rather than large genomic rearrangements. The prevalence of such rearrangement variants has been shown to vary significantly in different populations [29]. Large genomic rearrangements may account for up to 21.4 % of the BRCA inactivating variants in high-risk patients from Latin America and the Caribbean [30]. In Hispanics from the Northern California Breast Cancer Family Registry, the BRCA1 deletion of exon 9–12 represented over 10 % of the BRCA1 pathogenic variants identified [31]. In Puerto Rico, the BRCA2 exon 1–2 deletion is one of the three most frequent pathogenic variants, accounting for 18 % of the BRCA cases [32]. Less than half of the studies reviewed reported screening for large scale rearrangements and only four reported performing comprehensive screening through Multiplex Ligation-dependent Probe Amplification (MLPA) (Table 1). As a result of these factors, the prevalence and the diversity of the BRCA pathogenic variants may be underestimated in several of the published studies.

Despite those limitations, some observations stand out. In unselected breast cancer cases from Brazil [33], Colombia [34, 35], Cuba [36], Mexico [37, 38], and Peru [39], the prevalence ranged between 1.2 and 4.9 %, which is similar to what has been reported for US non-Hispanic White populations [40]. One exception is in the Bahamas, where it is estimated that 27.1 % of breast cancer cases were carriers of a BRCA pathogenic variant, regardless of age of onset or family history of cancers [41, 42].

Currently, recommendations to offer genetic testing for hereditary cancers are based on family history and/or personal history suggestive of Hereditary Breast and Ovarian Cancer. Recently, this practice has been challenged and screening every woman as part of the routine medical examination has been proposed [43]. The high prevalence in the Bahamas provides an argument in favor of a more aggressive BRCA screening approach in such populations.

It is expected that countries for which smaller cohorts were screened show less diversity in the BRCA variants identified, not because they are less genetically diverse but rather as a consequence of the limitations associated with sample size in characterizing rare variants. This is exemplified by Brazil [33, 44–48], Mexico [37, 38, 49–52], and in US Hispanics [31, 53–57] where the number of different pathogenic variants detected ranged from 37 to 45 as a result of over 1300 individuals screened (Table 2). Variants such as 185delAG, 5382insC, and R1443X are among the 20 most frequent BRCA1 variants reported by the Breast Cancer Information Core (BIC) database (http://research.nhgri.nih.gov/bic/), and it is therefore not surprising that they are recurrent in several countries of Latin America as well. In contrast, BRCA1 A1708E was among the 10 most frequent pathogenic variants in Latin America, observed in four different countries, but is not one of the most frequent BRCA1 variants overall. This represents an example of a recurrent pathogenic variant specific to these populations. Interestingly, the ratio of BRCA1 to BRCA2 carriers also shows significant variations across Latin America. In most populations, BRCA1 variants are more frequent than BRCA2, and this holds true for most countries of Latin America. However, in Costa Rica [58], Cuba [36], Puerto Rico [32], and Uruguay [59], over 80 % of the carriers had a pathogenic variant in BRCA2. This observation has important clinical implications as the characteristics of the cancer spectrum, and tumor pathology is expected to differ according to the gene mutated [60]. For instance, BRCA1 and BRCA2 carriers show differences in both overall risk of developing breast and ovarian cancer and age distribution of risk [13]. Cancers associated with BRCA1 germline mutations are more frequently medullary of high mitotic counts, while BRCA2-associated cancers have higher score for tubule formation with lower mitotic counts [61]. Compared to sporadic breast tumors, basal subtype markers are more common in tumors arising in BRCA1 carriers [62] but not in BRCA2 carriers [63]. In contrast, BRCA2-associated tumors are more likely to be of the luminal subtype and estrogen receptor positive when compared to controls [64].

Table 2

Recurrent BRCA1 and BRCA2 mutations in Latin America, the Caribbean, and US Hispanics

Country	Individuals screened n	Carriers n	Mutations n	Recurrent mutations1 n	Carriers with a recurrent mutation n (%)
Argentina	94	19	19	0	0
Argentina (Ashkenazi Jews)	40	17	3	3	17 (100)
Bahamas	204	47	11	6	42 (89.4)
Brazil	1408	82	37	9	54 (65.9)
Chile	380	40	18	12	30 (75.0)
Colombia	1195	63	10	3	56 (88.9)
Costa Rica	111	5	4	1	2 (40.0)
Cuba	307	7	6	1	2 (28.6)
Mexico	1305	128	45	15	101 (78.9)
Peru	266	13	5	3	11 (84.6)
Puerto Rico	23	11	6	3	8 (72.7)
Uruguay	42	6	6	0	0
US Hispanics	1486	173	41	17	149 (86.1)
Venezuela	58	9	8	1	2 (22.2)

1For any given country, a recurrent mutation is defined as a mutation identified in more than one unrelated BRCA carriers

In some countries, a few recurrent variants explain the majority of cases linked to BRCA-inactivation. As a result, a PCR-based MassARRAY (Sequenom) panel of recurrent mutations, the HISPANEL, was developed in the US and validated among US Hispanic and Mexican populations. Compared with direct sequencing, this approach was estimated to have a sensitivity of 68 % but for a fraction of the cost, which is an important factor to consider in countries where resources are limited. Such an approach could be considered for Colombia where despite having identified 63 carriers in 1195 individuals screened, three recurrent variants explained over 88 % of the cases [34, 35, 65, 66]. On the other hand, this strategy may not be adequate for countries such Argentina [67], Uruguay [59], and Venezuela [68] where most recurrent pathogenic variants are not frequent. (Table 2).

In addition, the question remains whether this panel could be transferable from one country to another. The E1308X variant is the most frequent in Puerto Rico and has been observed in the US but has not been observed in any other countries of Latin America. Within Latin America, only 8.02 % (n = 13) of the pathogenic variants reported were present in two or more countries. Caution should also be taken in studying US Hispanic to make inferences about the populations of origin of these immigrants. The BRCA2 6174delT variant was one of the most frequently observed in Latin America (except for Mexico) but has still not been reported in US Hispanics. Many of the recurrent variants found in Chile [69, 70] have not been observed in US Hispanics. Overall, of the 167 BRCA pathogenic variants identified in this literature review, only 10.4 % (n = 17) were shared between US Hispanics and Latin America. While these observations may be the result of the limited sample sizes available for some of the countries, it suggests that the Latin America immigrants established in the US might not represent the genetics of their populations of origin in their complexity. It is also a reflection of the demographics of the US Hispanic populations, where countries like Mexico and Puerto Rico are overrepresented. As illustrated by the network of interaction of recurrent BRCA variants between the Latin America countries (Fig. 1), it can be observed that the most frequent variants are more likely to be shared across countries, but a significant number of recurrent variants are found in one country only. Therefore, the available data, even though limited, suggest that the development of a low-cost Latin American screening panel that would be widely offered is unlikely as a result of the limited overlap in the spectrum of reported BRCA1 and BRCA2 variants in Latin America and US Hispanics.

Fig. 1

The network of recurrent BRCA1 (a) and BRCA2 (b) pathogenic variants reported in Latin America, the Caribbean, and US Latinos. Recurrent variants have been reported more than once within a country and/or have been observed in more than one country. The connections between the nodes generate a complete system of interactions between variants and the countries in which they have been detected. The nodes representing the countries are mapped on the network based on the proportion of shared variants with other Latin America countries. The size of the nodes representing the variants is proportional to the total number of observations, dashed edges were used for recurrent variants that were unique to a country, and thicker edges indicate variants that are shared in more countries. The blue node colors indicate countries for which at least one study conducted comprehensive BRCA1/2 analysis by direct sequencing, and the green nodes indicate countries for which BRCA analysis was conducted using mutation panels or indirect analysis methods. Darker nodes (dark blue or dark green) indicate countries for which at least one study conducted comprehensive large rearrangement screening, while the pale node colors (pale blue or pale green) indicate countries for which no comprehensive rearrangements were assessed. The network was generated with Cytoscape 3.2.1 [96]

Population history shaped the BRCA variant spectrum in Latin America

The genetic makeup of modern populations in Latin America is a combination of pre-Colombian and colonial heritage, both in the diversity of the gene pools imported in the Americas and their subsequent admixture. Accordingly, heterogeneity in admixture patterns has been shown to vary significantly across and within the continent [71-76]. From the 15th century, the European colonial migration to the New World nearly decimated the Native American populations [77]. European founders were mainly of Spanish and Portuguese origin but also reflected the diversity of the Iberian peninsula [71]. During the Atlantic trade between 1451 and 1870, an estimated nine million slaves were brought to the Americas from the West Coast of Africa [78]. In the context of testing for hereditary cancer predisposition variants, data from the 1000 Genomes Consortium demonstrated that rare variants are more likely to be specific to a continent or country than common variants [79], suggesting that one should account for the diversity of the populations inhabiting Latin America when designing screening and prevention strategies.

Some recurrent pathogenic variants in the populations from Latin America can be associated with documented migration events. The origin of the Jewish pathogenic variant BRCA1 185delAG can be traced back to 1492 when, coinciding with the start of the colonization of the Americas, Jews were forced to convert or be expelled from the Iberian Peninsula. In the view of the long-lasting genetic admixture of Sephardic and Ashkenazi Jews, and following migration of Jews into the countries of South and North America, it is not surprising that typical founder Jewish mutations are commonly found in the modern Argentina, Peru, Brazil, Chile, and US Hispanics. In some cases, haplotype analysis has confirmed that the origin of the 185delAG in populations from Latin America was in fact the same as the Jewish founder mutation [57].

Fewer recurrent variants are traced back to the African continent, despite a significant contribution of African ancestry to the genetic pool of some of the populations of Latin America. Among the factors proposed to explain, this observation is the exceptional genetic diversity both within Africa and in the numerous ethnic groups that were brought to the Americas during the Atlantic slave trade. One exception is the BRCA1 943ins10 mutation, which is the most frequently pathogenic variant reported in African-Americans by Myriad Genetics Laboratories, representing 10 % of the 279 African-American BRCA pathogenic variants [80]. The presence of a single haplotype in families from the Ivory Coast, Florida, Southeastern US, and the Bahamas is consistent with a founder effect originating in West Africa [81].

Taken together, these examples indicate that the mutation spectrum of each Latin American population is expected to be strongly linked to their migration history. Hence, one could extrapolate that the extent of the overlap in the frequent BRCA mutations observed between countries will be, at least in part, determined by the shared events and interchanges that characterize the migration history of each geographical region. The BRCA1 deletion of exons 9–12 is a recurrent pathogenic variant observed in unrelated families of Mexican origin, which are geographically dispersed in the US [31, 82]. Haplotype analysis pointed to a founder effect of a variant that would have originated in Amerindian or Mestizo populations [82]. Other examples include a BRCA1 3450del4 identified in multiple breast and ovarian cancer patients from Brazil [45, 47], Chile [70], and Colombia [34, 35, 65, 66], which is also common in breast cancer populations from Spain [83] and Portugal [84]. In contrast, the BRCA1 5382insC founder pathogenic variant is most frequently reported in Brazil by several independent studies [33, 44, 45, 48] but has not been observed elsewhere in South America with the exception of an Ashkenazi community in Argentina [67]. This indicates that the genetic background of the Latin American populations is also shaped by events leading to unique population structures within and between countries.

Caution should be taken when making inferences about the origin of BRCA variants based solely on the co-occurrence in two populations. In the absence of haplotype analysis, one cannot distinguish whether a variant has migrated from one historically linked geographic area to another or is the result of independent mutational events. Therefore, not all carriers of the recurrent pathogenic variants or well-known founder mutations are expected to share a common ancestor. For example, BRCA2 3034del4 is a recurrent variant, which was also observed as a de novo germline mutation in a case of early onset breast cancer with no strong family history of cancer [85]. In families of Northern Europe Caucasian ancestry, this same mutation was observed in seven different countries and showed considerable haplotype diversity [86]. Haplotype analyses have identified multiple origins for several other recurrent mutations, including BRCA1 185delAG [87]. This suggests that some regions of the BRCA1 and BRCA2 genes might be prone to mutations. It is also noteworthy in light of the small proportion of studies who conduct mutation screening in the context of haplotype analysis. Finally, de novo variants may also be underreported as the majority of individuals undergoing BRCA testing are selected for having strong family history of cancer.

Cancer genetic testing awareness and access in Latin American populations

While hereditary clinical testing of Latin American and US Hispanic populations could greatly benefit from a better understanding of the mutation spectrum in the BRCA genes, social-economic aspects of genetic testing will also need to be addressed to improve access. In its policy statement on genetic and genomic testing, ASCO emphasizes the role of the informed consent process and recommends that cancer genetic susceptibility testing be conducted in the context of pre- and post-testing genetic counseling [88]. Positive outcomes associated with testing may be limited in the absence of genetic counseling and integrated clinical management structure ensuring that carriers are engaged in appropriate screening and prevention programs. Given that Hispanics in the US are 1.8 times more likely to receive an inconclusive result (variant of uncertain significance) [80], the participation of genetics professionals pre- and post-testing becomes especially important to provide support to the patients and physicians. Finally, a negative test results in the absence of a known mutation in the family may provide a false reassurance, especially when testing is not conducted in the context of extended panels of genes [89].

Studies reporting on awareness and access to genetic testing in Latin America are sparse, but the situation in the US has been more documented. In a cross-sectional analysis of 46,276 women who underwent BRCA genetic testing between 1996 and 2006, only 4.2 % were of Latin American ethnicity [80]. In a US sample of 1414 women diagnosed with breast cancer at or before 40 years of age between 2004 and 2007, Hispanic women were significantly less likely to be tested for BRCA1 and BRCA2 mutations [90]. This disparity in access to cancer genetic testing is especially alarming knowing that the Hispanic population accounts for approximately 16.3 % of the US population [21]. Genetic testing awareness has been shown to be significantly lower in Hispanics of the US when compared to non-Hispanic whites [91]. Acculturation, especially the use of the English language, strongly correlated with awareness of genetic testing for cancer in the US [92]. Once informed, participants held favorable attitudes toward risk assessment and counseling [93, 94]. In some parts of Latin America, limited resources both monetary and in the availability of trained genetic professional may impede accessibility to cancer genetic testing. Recently, BRCA1/2 telephone counseling was shown to be as effective in providing psychological support and guiding informed decisions [95]. This might contribute to improve access to genetic counseling in Latin American, especially in rural setting.

Conclusions

Therefore, for the populations of Latin America and US Hispanics to benefit from genetic-based cancer prevention options, a strategy that combines acquiring a better knowledge of the variants underlying hereditary cancers in those population and improved access to genetic testing will need to be developed. From the data available, the following recommendations emerge: (1) If panels of mutation are the only economically feasible approach, they should be developed after comprehensive analysis of a large series of samples rather than testing panels that have been developed from other populations; (2) large genomic rearrangements should be included; and (3) proper clinical infrastructure including genetic counseling should be widely available.

Protocol for the identification and selection of the studies to be included. Pubmed database was searched for combination of the following MeSH terms: “Genes, BRCA1” or “Genes, BRCA2” and “South America” or “Central America” or “Caribbean Region” or “Hispanic Americans” or “Mexico” and “Mutation” or “Hereditary Breast and Ovarian Cancer Syndrome”. Please note that Mexico was searched separately as it is not listed as a sub-category of “Central America” MeSH term. A total of 48 studies were identified through that search, out of which 21 met the eligibility criteria. Reasons for excluding a study included 1) no mutations identified in the sample analyzed (n = 4), sample analyzed is the same as another study already included (n = 2), gene analyzed is other than BRCA1 or BRCA2 (n = 1), full text not available online (n = 1), study population is not from Latin America, Brazil or US Hispanic (n = 1), study does not conduct mutation analysis of BRCA1 and BRCA2 (n = 10). The literature cited from selected papers was systematically searched and additional eligible studies were identified (n = 11). A total of 33 eligible studies were included in the analysis. Supplementary material 1 (JPEG 83 kb)

Nomenclature of the pathogenic variants identified in US Hispanics, Latin America and the Caribbean. Designations from the Breast Cancer Information Core (BIC, https://research.nhgri.nih.gov/projects/bic/Member/index.shtml), Human Genome Variation Society (HGVS, http://www.hgvs.org/), the single nucleotide polymorphisms database (dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/) and the Breast ExAC Exome Aggregation Consortium (http://exac.broadinstitute.org/) are provided. The total number of times and the countries where each mutation was reported is listed for each variant. NR not reported, N/a not applicable. Supplementary material 2 (XLSX 27 kb)